Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.13.

A number of research analysts have recently commented on the company. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday. B. Riley restated a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total transaction of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at $40,502,093.85. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 275,880 shares of company stock valued at $4,034,037. 4.30% of the stock is owned by company insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. increased its position in shares of Arrowhead Pharmaceuticals by 11.6% during the fourth quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company's stock valued at $525,000 after purchasing an additional 2,907 shares during the period. Raymond James Financial Inc. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $651,000. Empowered Funds LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $268,000. KLP Kapitalforvaltning AS acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $434,000. Finally, Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $38,622,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $15.34 on Friday. The firm has a 50 day moving average of $13.29 and a two-hundred day moving average of $17.83. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $30.41. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -2.97 and a beta of 0.89. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the prior year, the company posted ($1.02) earnings per share. As a group, equities analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.